ENGN vs YDDL Comparison

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of the Philippines. The company processes raw materials and generates final products that include copper alloy ingots, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap, and industrial recycling. The company operates and manages its business as a single segment and has one operating and reportable segment, trading of recycled scrap metals. Geographically, it generates the majority of its revenue from China.